Verastem Inc (VSTM)

Apr 14, 2026

PI3K Inhibitor Drug Class Market (2026-2033) | PI3Kα, PI3Kβ, - openPR.com

Apr 14, 2026

Apr 13, 2026

Chipmakers Recap: How is Verastem Inc managing supply chain issues2026 Support & Resistance & Long Hold Capital Preservation Tips - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

Aug Wrap: What analysts say about Verastem Inc stock2026 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn

Apr 13, 2026

Apr 13, 2026

H.C. Wainwright reiterates Verastem stock rating on durable trial data By Investing.com - Investing.com Canada

Apr 13, 2026

Apr 11, 2026

Sentiment Recap: What analysts say about Verastem Inc stockTrade Entry Report & AI Optimized Trade Strategies - baoquankhu1.vn

Apr 11, 2026

Apr 10, 2026

Verastem Oncology’s combo shows two-year durability in ovarian cancer - MSN

Apr 10, 2026

Apr 10, 2026

Fed Meeting: What is the Moat Score of Verastem IncQuarterly Earnings Report & Consistent Income Trade Recommendations - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

Today's Analyst Rating Data for VSTM: Maintained Buy Rating | VS - GuruFocus

Apr 10, 2026

Apr 10, 2026

Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 | VSTM Stock News - GuruFocus

Apr 10, 2026

Apr 10, 2026

Today's Analyst Rating for VSTM: Maintains Buy Rating at $18.00 - GuruFocus

Apr 10, 2026

Apr 10, 2026

Verastem stock maintains Buy rating at BTIG on durable trial data - Investing.com Canada

Apr 10, 2026

Apr 10, 2026

Verastem (VSTM) Presents Positive Two-Year Data for Ovarian Canc - GuruFocus

Apr 10, 2026

Apr 10, 2026

Verastem’s cancer drug combo shows durability in 2-year data By Investing.com - Investing.com India

Apr 10, 2026

Apr 10, 2026

Verastem’s cancer drug combo shows durability in 2-year data - Investing.com

Apr 10, 2026

Apr 10, 2026

Verastem Oncology announces two-year median follow-up data on Avmapki® Fakzynja® combination therapy - marketscreener.com

Apr 10, 2026

Apr 10, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data On Avmapki® Fakzynja® Combination Therapy - TradingView — Track All Markets

Apr 10, 2026

Apr 10, 2026

Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s C - Business Wire

Apr 10, 2026

Apr 10, 2026

Weekly Trades: What analysts say about Verastem Inc stockCEO Change & Weekly High Potential Alerts - baoquankhu1.vn

Apr 10, 2026

Apr 10, 2026

VSTM Stock Price, Quote & Chart | VERASTEM INC (NASDAQ:VSTM) - ChartMill

Apr 10, 2026

Apr 09, 2026

Verastem (Nasdaq: VSTM) boosts equity and ESPP share pools for employees - Stock Titan

Apr 09, 2026

Apr 05, 2026

Understanding Momentum Shifts in (VSTM) - Stock Traders Daily

Apr 05, 2026

Apr 04, 2026

Working capital per share of Verastem, Inc. – MUN:2VSA - TradingView — Track All Markets

Apr 04, 2026

Apr 04, 2026

VSTM Earning Date, Earning Analysis and Earning Prediction - Intellectia AI

Apr 04, 2026

Apr 04, 2026

SG Americas Securities LLC Purchases 378,958 Shares of Verastem, Inc. $VSTM - MarketBeat

Apr 04, 2026

Apr 04, 2026

Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 04, 2026

Apr 04, 2026

Verastem, Inc. (VSTM) stock price, news, quote and history - Yahoo Finance UK

Apr 04, 2026

Apr 03, 2026

Earnings call transcript: Verastem’s Q4 2025 results highlight oncology growth - Investing.com

Apr 03, 2026

Apr 03, 2026

Alison Lawton and Michael Kauffman Join Verastem Board of Directors - Yahoo

Apr 03, 2026

Apr 02, 2026

Verastem, Inc. (2VSA.F) stock price, news, quote and history - Yahoo Finance Singapore

Apr 02, 2026

Apr 02, 2026

Verastem Oncology announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com

Apr 02, 2026

Apr 02, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Apr 02, 2026

Apr 02, 2026

Stephen Sherwin, M.D., Joins Verastem Board of Directors - yahoo.com

Apr 02, 2026

Apr 02, 2026

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - businesswire.com

Apr 02, 2026

Mar 30, 2026

Verastem (VSTM): Jefferies Lowers Price Target but Retains 'Buy' Rating | VSTM Stock News - GuruFocus

Mar 30, 2026

Mar 30, 2026

Verastem's (VSTM) "Buy" Rating Reaffirmed at Jefferies Financial Group - MarketBeat

Mar 30, 2026

Mar 30, 2026

Jefferies Initiates Verastem(VSTM.US) With Buy Rating, Announces Target Price $15 - Moomoo

Mar 30, 2026

Mar 30, 2026

Verastem, Inc. (NASDAQ:VSTM) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Mar 30, 2026

Mar 27, 2026

Jefferies lowers Verastem stock price target on valuation refresh - Investing.com UK

Mar 27, 2026

Mar 27, 2026

Jefferies lowers Verastem stock price target on valuation refresh By Investing.com - Investing.com India

Mar 27, 2026

Mar 27, 2026

Vanguard disaggregates holdings; reports 0 shares of Verastem (NASDAQ: VSTM) - Stock Titan

Mar 27, 2026

Mar 26, 2026

Cancer Stocks Worth Considering as Breakthroughs Transform the Worldwide Oncology Industry - Bitget

Mar 26, 2026

Mar 23, 2026

Verastem (VSTM) CFO receives 57-share stock award in Form 4 - stocktitan.net

Mar 23, 2026

Mar 22, 2026

Market Moves: What analysts say about Verastem Inc stock2026 Earnings Surprises & Weekly Watchlist for Consistent Profits - baoquankhu1.vn

Mar 22, 2026

Mar 19, 2026

Verastem: Maintaining "Buy" As 1st Half 2026 Catalysts In Play (NASDAQ:VSTM) - Seeking Alpha

Mar 19, 2026

Mar 18, 2026

Verastem Oncology drops despite Q3 double beat - MSN

Mar 18, 2026

Mar 18, 2026

AACR Meeting spotlights Verastem, Inc. progress on oral KRAS G12D inhibitor - Traders Union

Mar 18, 2026

Mar 17, 2026

FinancialContentVerastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 - FinancialContent

Mar 17, 2026